CaroGen Corporation is an emerging biopharmaceutical company with an entirely new platform technology. CaroGen is developing a pipeline of innovative and transformative immunotherapies for various diseases including colorectal cancer.
CaroGens lead program on Chronic Hepatitis B Viral Infection (CHB) in collaboration with Yale School of Medicine and Albany Medical College, while Colon Cancer Immunotherapy in collaboration with researchers at the University of Connecticut.
CaroGen is developing a pipeline of innovative and transformative immunotherapies for various diseases including colorectal cancer.
CaroGens lead program on Chronic Hepatitis B Viral Infection (CHB) in collaboration with Yale School of Medicine and Albany Medical College, while Colon Cancer Immunotherapy in collaboration with researchers at the University of Connecticut.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/carogen-corporation” connections=”true” suffix=””]
CaroGens proprietary virus-like vesicle (VLV) technology is a hybrid of components from two unrelated animal viruses: the alphavirus Semliki Forest virus (SFV) and rhabdovirus vesicular stomatitis virus (VSV), producing particles that have limited replication-competence in vivo. The VLVs generated can enter into cells of treated subject where, although limited, they propagate sufficiently to express the VLV-encoded antigens to be presented to the host immune system.
In Nov 2016, CaroGen signed a research collaboration with The University of Connecticut (UCONN), aimed at developing a therapeutic vaccine for treatment of patients with colon cancer. Under ther terms, CaroGens proprietary technology platform will be applied to a specific target of UCONN and Carogen will financially support the program. Presently under this program proteins have been selected for VLV-based delivery and is undergoing lead optimization.
In Oct 2016, CaroGen raised $1 Mn through GP Fortune Investment Partners (GPFI), LLC,. Also, GPFI agreed to invest additional $7 Mn in CaroGen over the next 36 months based on achieving certain HBV preclinical milestones. Earlier, In Dec 2014, CaroGen recieved funding of $500,000 from the Connecticut Bioscience Innovation Fund (CBIF).
Recover your password.
A password will be e-mailed to you.